Tradestie Institutional Equity Comparison Engine

ACIU vs MNOV โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MNOV Overall Edge

MNOV Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Medicinova, Inc. (MNOV) driven by superior Momentum & Technical, Options & Structure while ACIU counters with relative strength in Valuation, Growth & Margin. Fundamentally, ACIU trades at 3.4x Forward P/E with -190.8% operating margin (+245.5% YoY revenue) versus MNOV at 8.5x Forward P/E and -1232.2% operating margin (+12.4% YoY). In options structure, ACIU sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against MNOV sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ACIU
ACIU 3.4x vs MNOV 8.5x Fwd P/E
Growth & Margin Winner ACIU
Op Margin -190.8% vs -1232.2% ยท YoY +245.5% vs +12.4%
Momentum & Technical Winner MNOV
1Y -37.5% vs -8.4% ยท 52W Pos 1% vs 3%
Options & Structure Winner MNOV
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (50th %ile IV)
ACIU NASDAQ
AC Immune SA
Pharmaceutical Preparations
$1.95
-8.45% 1D
Market Cap $211.8M
1M Return -22.0%
1Y Return -37.5%
Forward P/E 3.4x
Unified AI Score
47.3 / 100 HOLD
Tech 40.0 Fund 70.0 Flow 50.0 Mom 78.9
MNOV NASDAQ
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
1M Return -7.09%
1Y Return -8.39%
Forward P/E 8.5x
Unified AI Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ACIU -37.5% MNOV -8.39% Spread: +29.11 pp (MNOV Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ACIU TTM Op. Margin: -190.8% MNOV TTM Op. Margin: -1232.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACIU vs MNOV. Trailing 12-month operating profitability (ACIU -190.8% vs MNOV -1232.2%) and valuation multiples (ACIU 3.4x vs MNOV 8.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ACIU (5) vs MNOV (5)
Institutional Metric ACIU MNOV Criterion Row Winner
Market Capitalization Scale $211.8M $65.1M Larger Scale ACIU
Trailing P/E Ratio Valuation 4.9x 8.5x Lower Multiple ACIU
Forward P/E Ratio Valuation 3.4x 8.5x Lower Multiple ACIU
Revenue Growth (YoY) Growth +245.5% +12.4% Higher Growth ACIU
Operating Margin (TTM) Profitability -190.8% -1232.2% Higher Margin ACIU
Net Profit Margin Profitability -181.9% 0.0% Higher Margin MNOV
Return on Equity (ROE) Capital Efficiency -80.7% -24.8% Higher ROE MNOV
52-Week Range Position Momentum 1% ($2โ€“$4) 3% ($1โ€“$4) Stronger Trend MNOV
Beta / 30D Volatility Risk Regime 1.42ฮฒ ยท 80% Vol 0.59ฮฒ ยท 38% Vol Lower Realized Risk MNOV
Unified Institutional Score Composite Signal 47.3 / 100 (HOLD) 50.2 / 100 (HOLD) Higher Composite MNOV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ACIU vs MNOV Buy Guide
ACIU UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ACIU Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MNOV UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MNOV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ACIU nor MNOV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.